Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin in the Prevention of Post-Coronary Intervention Acute Kidney Injury

NCT05435235 is registered in ClinicalTrials.gov with Albert Einstein Healthcare Network as lead sponsor.

NCT NCT05435235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05435235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin in the Prevention of Post-Coronary Intervention Acute Kidney Injury
Lead sponsor
Albert Einstein Healthcare Network
Phase
Phase 4
Overall status
Suspended
Start date
September 1, 2024
Completion date
June 30, 2025
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, percutaneous coronary intervention